There are numerous challenges associated with diagnosing and managing interstitial lung diseases (ILDs), as symptoms often mimic a wide range of medical conditions. For those who want to learn more about this complex group of diseases, the ATS ILD Education Center (ILDEC) can be a go-to resource for cutting-edge insights on ILDs. Stay ahead with expert-led education on recognizing, diagnosing, and managing ILD to improve patient outcomes. Explore the latest research, emerging therapies, and clinical best practices—all in one place.

The ATS ILDEC was developed by a panel of ILD experts who believe improving patient outcomes begins with an accurate, early diagnosis. This educational site features tools and resources for practicing pulmonologists, general practitioners, rheumatologists, radiologists, pathologists, and trainees.

Attendees of the ATS 2025 International Conference can learn more by visiting the ILDEC located in Hall D (South Building, Exhibition Level) between the Networking Super Center and the ATS Center.

Those interested in expanding their knowledge of ILDs and the ILDEC should also attend the scientific symposium, “The Evolving Landscape of ILD: Diagnosis, Prognostic Indicators, and New Treatments,” from 12:15 to 1:45 p.m. PT in Room 25, Hall E (North Building, Exhibition Level) of the Moscone Center on Monday, May 19.

The session will illustrate key gaps in diagnosing and managing ILDs by enhancing clinicians’ understanding of these conditions in numerous areas, starting with differential diagnoses based on causes, clinical, and/or radiologic features.

The primary challenge with ILDs is getting to the right diagnosis, explained Joyce Lee, MD, ATSF, professor of medicine-pulmonary sciences and critical care at the University of Colorado Anschutz Medical Campus and session organizer. “Treatment depends on ILD diagnosis, and diagnosis is not always easy or straightforward. Therefore, increasing awareness of ILD and ILD diagnosis, through initiatives like the ILDEC, is critical.”

The session will also spotlight the role of inflammation and fibrosis in ILD progression, helping clinicians identify markers of disease progression, such as forced vital capacity decline, to improve prognosis assessment and treatment decisions.

Lastly, presenters will educate attendees on therapeutic options for ILDs, including current therapies and emerging therapeutic approaches, empowering clinicians to optimize patient care with the latest evidence-based treatment options.

“Treatment can be difficult, and the treatment landscape is changing — so providing support and resources for the existing therapies and dissemination of evolving treatment strategies is facilitated by initiatives like the ILDEC,” Dr. Lee said.

Don’t miss this expert-led symposium and be sure to visit the ILDEC booth while attending ATS 2025 San Francisco to learn how to take advantage of all the provider resources available to help optimize care for patients with ILDs.

Funding for this project was provided by Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim Pharmaceuticals, Inc. did not have input on content development.